Hikma Pharmaceuticals PLC stock (GB00B128J450): London-listed generics group in focus after buyback and analyst consensus

Hikma Pharmaceuticals PLC shares in the United Kingdom remain in focus after a recently expanded share buyback program and an active analyst consensus, with the London-listed generics specialist trading steady ahead of potential further newsflow.

Hikma Pharmaceuticals PLC shares on the London Stock Exchange continue to attract attention from U.K. investors after the company confirmed an extended share buyback program alongside a solid analyst backdrop, keeping the FTSE-listed generics producer on the radar despite a broadly mixed pharmaceuticals tape.

According to AJ Bell pricing data for the London Stock Exchange, Hikma Pharmaceuticals PLC last traded around 1,476 pence on 05/29/2026 under the ticker HIK, giving investors in the United Kingdom a clear reference point for the stock as of late May and situating the move within the domestic equity market context.AJ Bell as of 05/29/2026

As part of its capital allocation strategy, Hikma has been running a share repurchase program in London, with ad-hoc and exchange disclosures indicating ongoing daily buyback transactions that support earnings per share metrics and signal balance-sheet flexibility, even if the total size of the program remains modest relative to its overall market capitalization.Ad-hoc-news.de overview as of 05/29/2026

From a home-country perspective, Hikma is headquartered in London in the United Kingdom and lists its primary equity line on the London Stock Exchange in sterling, making developments in the British generics and injectable markets as well as U.K. institutional flows particularly relevant for the stock’s performance.

While the central listing is in London, the company’s shares can also be accessed by German investors via secondary trading venues such as Tradegate, where the stock has recently changed hands in euro, adding an additional cross-border liquidity pool for European retail accounts alongside the U.K. home market.

At the same time, the group continues to invest in its U.S. manufacturing base, with JobOhio confirming in a recent release that Hikma plans to invest a total of USD 267 million across its Columbus and Bedford facilities, including USD 216 million for oral solid and nasal inhalation operations and USD 51 million to expand injectable capacity, underlining the importance of the American generics market to its long-term growth ambitions.JobOhio as of 04/2026

The stock traded at 1,476 pence on 05/29/2026 on the London Stock Exchange, according to AJ Bell as of 05/29/2026.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Hikma
• Sector/industry: Pharmaceuticals and generics manufacturing
• Headquarters/country: London, United Kingdom
• Core markets: United Kingdom, United States, Middle East and North Africa
• Key revenue drivers: Branded and unbranded generics, injectable medicines and related contract manufacturing
• Home exchange/listing venue: London Stock Exchange (HIK)
• Trading currency: GBP

Hikma Pharmaceuticals PLC: core business model

Hikma Pharmaceuticals PLC positions itself as a diversified medicines producer, focusing on generic and injectable therapies as well as selected branded drugs that are distributed across key regions such as the United Kingdom, the United States and the Middle East.

What banks and research houses say about Hikma Pharmaceuticals PLC

Analyst coverage for Hikma Pharmaceuticals PLC remains active, with MarketBeat compiling research from several houses that follow the London-listed stock and summarizing the consensus stance and associated price targets for the U.K. equity.

According to MarketBeat as of 05/29/2026, the consensus across 5 analysts is rated as a buy, with an average 12-month price target of 2,128 pence, based on data that also show a high estimate of 2,400 pence and a low estimate of 1,800 pence for the London-listed shares.MarketBeat as of 05/29/2026

The same MarketBeat compilation indicates that the average target implies an expected upside of roughly 44 percent from the 1,476 pence share price recorded on 05/29/2026, underscoring that the analyst community continues to see valuation headroom relative to current trading levels.MarketBeat as of 05/29/2026

Conclusion

Hikma Pharmaceuticals PLC remains an actively traded U.K. generics name, with its London-listed shares supported by an ongoing buyback program and increased U.S. investment that together highlight management’s confidence and expansion agenda.

The analyst consensus compiled by MarketBeat, pointing to an average target price materially above the late-May spot level, adds a further layer of context for investors assessing the stock’s current valuation on the London Stock Exchange.

How these factors ultimately interact with regulatory developments in key markets and execution on the Ohio capacity expansion will be central to whether the share price can narrow the gap toward the analyst targets over the coming 12 months.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.